Sarlósejtes vérszegénység: vizsgálatok itt: Olaszország
14 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 14.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Where
- Ferrara, Genoa, Modena, Monza, Naples, Palermo, Rome, Verona
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07224360 · EU 2025-521154-42-00 - 3. fázisNot yet taking people in OlaszországA Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
- Where
- Genoa, Modena, Naples, Palermo
- Életkor
- 12 év and over
- People
- 159 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT07656415 · EU 2026-526778-18-00 - 3. fázisTaking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- Florence, Genoa, Milan, Naples, Orbassano, Palermo, Rome, Verona
- Életkor
- 10 év to 65 év
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865 - 2. fázisBefejeződöttSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Where
- Genoa, Modena, Orbassano, Padova, Palermo, Rome, Verona
- Életkor
- 12 év and over
- People
- 70 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06699849 · EU 2024-513440-29-00 - 3. fázisNot yet taking people in OlaszországA research study to evaluate how well etavopivat works in children with sickle cell disease
- Where
- Brescia, Catania, Modena, Naples, Padova, Palermo
- Életkor
- Up to 17 év
- People
- 27 worldwide
- Run by
- Novo Nordisk A/S
See details and how to join2025-524464-38-00 - 3. fázisTaking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Orbassano, Padova, Pavia
- Életkor
- 2 év and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - 3. fázisTaking peopleA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Brescia, Catania, Modena, Monza, Naples, Orbassano, Padova, Palermo, Verona
- Életkor
- 12 év and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - 2/3. fázisNot yet taking people in OlaszországA Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Where
- Genoa, Naples, Padova, Palermo, Verona
- Életkor
- 12 év to 64 év
- People
- 389 worldwide
- Run by
- Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00 - 1/2. fázisNot yet taking people in OlaszországA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Where
- Milan, Padova, Verona
- Életkor
- 18 év and over
- People
- 224 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06481306 · EU 2023-510283-12-00 - 3. fázisTaking peopleA Long-term Follow-up Study in Participants Who Received CTX001
- Where
- Rome
- Életkor
- 2 év to 64 év
- People
- 160 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00 - 4. fázisFut, nem toborozRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- Where
- Padova
- Életkor
- 6 hónap to 100 év
- People
- 130 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04657822 · EU 2024-510734-41-00 - 3. fázisTaking peopleEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- Where
- Rome
- Életkor
- 12 év to 35 év
- People
- 26 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT05477563 · EU 2024-514641-12-00 - 3. fázisNot yet taking people in OlaszországA Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects with Severe Sickle Cell Disease, βS/βC Genotype
- Where
- Rome
- Életkor
- Up to 64 év
- People
- 5 worldwide
- Run by
- Vertex Pharmaceuticals Inc.
See details and how to join2023-503247-34-00 - No phaseNot yet taking people in OlaszországStudy of the Role of Genetic Modifiers in Hemoglobinopathies
- Where
- Turin
- Életkor
- 2 év and over
- People
- 30 000 worldwide
- Run by
- Cyprus Institute of Neurology and Genetics
See details and how to joinNCT05799118